clinical trials for glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy We run “head-to-head” clinical trials

and optic nerve decompression surgery to try to relieve pressure on the optic nerve

In a retrospective cohort study including 7,044 patients with T2D, obesity (BMI 27 kg/m 2 ) and HFpEF, combination therapy with an SGLT2i and GLP-1 RA showed a lower risk of HF exacerbation, all-cause emergency department visits and new-onset kidney injury compared with patients only receiving SGLT2i

The biomechanical relationship between body weight and joint loading provides a clear physiological basis for understanding how GLP-1-induced weight loss may alleviate joint pain

Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection" Thomas von Erlach, PhD, Vivtexs CEO and co-founder, said: Making biologics oral has been one of the most difficult challenges in drug delivery

Prevents Type 2 Diabetes Progression By improving insulin sensitivity and beta-cell function Supports Cardiovascular Health Reduces blood pressure, LDL cholesterol, and inflammation Lowers Risk of Fatty Liver Disease (NAFLD/NASH) Helps reduce liver fat accumulation Improves PCOS Symptoms Regulates ovulation, insulin resistance, and weight in women with PCOS May Benefit Neuroprotection Early studies suggest a role in reducing neuroinflammation and cognitive decline Contraindications These GLP-1s are generally well-tolerated, but some patients should not take them